Drugs / NKG2D CAR T-cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04658004 | Jan 2021 → Jan 2024 overdue | acute myeloid leukemia | Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT07021534 | Jun 2025 → Dec 2026 expected | — | Zhejiang University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NKG2D CAR T-cells | “NKG2D CAR-T cells (Over a two-day period, CAR-T cells are administered via intravenous infusion on two consecutive occasions.” NCT07021534 ↗ |
| Modality | Cell therapy | “CAR cellular therapy” NCT07021534 ↗ |
| Route | Intravenous | “Each subject receive NKG2D CAR T-cells by intravenous infusion” NCT04658004 ↗ |